论文部分内容阅读
目的观察替吉奥联合多西他赛治疗晚期胃癌患者的疗效和不良反应。方法选择23例经病理学或细胞学确诊的晚期胃癌患者,给予替吉奥胶囊70 mg/(m2.d),分2次餐后口服,第1～14天;多西他赛75 mg/m2,静脉滴注。3周重复为1个周期,至少完成2个周期后评价有效率、不良反应等。结果 23例患者中,完全缓解1例,占4.3%;部分缓解9例,占39.1%;疾病稳定8例,占34.8%;疾病进展5例,占21.7%。不良反应主要为白细胞减少、疲乏、消化道反应、食欲减退等,均可耐受。结论替吉奥联合多西他赛治疗晚期胃癌患者疗效确切,不良反应较轻,患者耐受性较好。
Objective To observe the curative effect and adverse reactions of treatment of advanced gastric cancer in patients with gastric cancer treated with tiotropium and docetaxel. Methods Twenty-three patients with advanced gastric cancer diagnosed by pathology or cytology were given 70 mg / (m2.d) of tegaserod capsules orally twice daily for 1 to 14 days and docetaxel 75 mg / m2, intravenous infusion. 3 weeks to repeat for a period of at least 2 cycles to complete the evaluation of the effectiveness of adverse reactions. Results Among the 23 patients, complete remission was achieved in 1 case (4.3%), partial remission in 9 cases (39.1%), stable disease in 8 cases (34.8%) and disease progression in 5 cases (21.7%). Adverse reactions mainly leukopenia, fatigue, gastrointestinal reactions, loss of appetite, etc., can be tolerated. Conclusion Treatment of advanced gastric cancer with getigoc and docetaxel is effective, with less adverse reactions and better tolerability.